greeksoup/ stock research
Stock research / United States / BDX · Surgical & Medical Instruments & Apparatus · NYSE

Becton Dickinson & Co. (BDX)

Results announcedQ4 FY2026quarter ended 30 September 2026, announced 5 November 2026

Net income$696 millionup 41.2% on Q4 FY2025
Diluted EPS$2.54$1.72 a year earlier

From the company's results press release. The tables update when the 10-Q or 10-K is filed. Read the results · Read the release

Becton, Dickinson and Company, known as BD, is a medical technology company that develops, manufactures and sells medical supplies, devices, laboratory equipment and diagnostic products. Its customers are healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The work it names runs across medication management and patient safety, infection prevention, surgical and interventional procedures, drug delivery, anesthesiology care, diagnosis of infectious diseases and cancers, and cellular research. It was incorporated in New Jersey in November 1906, as successor to a New York business started in 1897, and its executive offices are in Franklin Lakes, New Jersey.

Becton Dickinson & Co.

Becton, Dickinson and Company, known as BD, is a medical technology company that develops, manufactures and sells medical supplies, devices, laboratory equipment and diagnostic products. Its customers are healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The work it names runs across medication management and patient safety, infection prevention, surgical and interventional procedures, drug delivery, anesthesiology care, diagnosis of infectious diseases and cancers, and cellular research. It was incorporated in New Jersey in November 1906, as successor to a New York business started in 1897, and its executive offices are in Franklin Lakes, New Jersey.

At 30 September 2025 the business ran in three worldwide segments, BD Medical, BD Life Sciences and BD Interventional. Effective 1 October 2025 it reorganised into five separately managed segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences, the last remaining part of BD until the Waters transaction described below completes.

BD Medical

Sold mainly to hospitals and clinics, physicians' offices, consumers and retail pharmacies, public health agencies, pharmaceutical companies and healthcare workers. Medication Delivery Solutions covers peripheral intravenous catheters, central lines, acute dialysis catheters, ultrasonic vascular access imaging, vascular care such as lock solutions and prefilled flush syringes, skin antiseptics and dressings, needle-free connectors, closed-system drug transfer devices, hypodermic and anesthesia needles, enteral syringes and sharps disposal systems. Medication Management Solutions covers infusion pumps and their disposables and fluids, medication compounding workflow systems, automated dispensing and supply management, and the informatics behind enterprise medication management. Pharmaceutical Systems makes prefillable drug delivery systems, including prefillable syringes and self-injection systems, supplied to pharmaceutical companies as the containers for injectable products that then reach the market as drug and device combinations. Advanced Patient Monitoring covers hemodynamic monitoring used to measure heart function and fluid status in surgery and intensive care, including tissue oximetry, pulmonary artery catheters and blood pressure measurement.

BD Life Sciences

Products for the safe collection and transport of diagnostic specimens, the instruments and reagents that detect infectious diseases, healthcare-associated infections and cancers, and research and clinical tools for studying cells. Customers are hospitals, laboratories and clinics, blood banks, healthcare workers, physicians' offices, academic and government institutions and pharmaceutical and biotechnology companies. Diagnostic Solutions covers automated blood culturing and tuberculosis culturing, microorganism identification and drug susceptibility systems, microbiology laboratory automation, culture media, molecular testing, and rapid point-of-care respiratory assays. Biosciences covers fluorescence-activated cell sorters and analyzers, antibodies and kits for cell analysis, reagents for research, single-cell gene and protein expression analysis, and clinical oncology and transplantation reagents. Specimen Management covers blood collection systems, safety-engineered wingsets, needles and tubes, arterial blood gas devices and urine collection kits.

BD Interventional

Vascular, urology, oncology and surgical specialty products, either used once and discarded or implanted temporarily or permanently, sold to hospitals, ambulatory surgery centres, individual professionals, extended care and alternate site facilities and to patients through the Homecare business. Surgery covers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery and surgical infection prevention products. Peripheral Intervention covers angioplasty balloon catheters, radiofrequency ablation catheters, peripheral vascular stents and stent grafts, vascular grafts, drug coated balloons, ports, biopsy, chronic dialysis, vena cava filters, drainage products, and atherectomy and thrombectomy systems. Urology and Critical Care covers urine management and measurement, indwelling, intermittent and external urine catheters, kidney stone management, targeted temperature management and fecal management devices.

What has come in and what is going out

On 3 September 2024 BD completed the acquisition of Edwards Lifesciences' Critical Care product group, renamed BD Advanced Patient Monitoring, for consideration with a fair value of $3.914 billion, funded with cash on hand from earlier debt issuance and commercial paper borrowings.

On 13 July 2025 BD agreed to combine its Biosciences and Diagnostic Solutions business with Waters Corporation in a Reverse Morris Trust transaction: those businesses would be spun off to BD shareholders and simultaneously merged with a subsidiary of Waters, leaving BD shareholders with approximately 39.2% of the combined company and existing Waters shareholders approximately 60.8%. The filing states that BD expects to receive a cash distribution of approximately $4 billion prior to completion, subject to adjustment for cash, working capital and indebtedness, and that Waters is expected to assume approximately $4 billion of incremental debt. The transaction is expected to close around the end of the first quarter of calendar 2026, subject to regulatory approvals, a Waters shareholder vote, a private letter ruling from the Internal Revenue Service and other customary conditions.

Two earlier disposals are also described. In August 2023 BD sold the Interventional segment's Surgical Instrumentation platform, recognising a pre-tax gain of approximately $268 million. On 1 April 2022 it completed the separation of its Diabetes Care business as Embecta Corp., a separately listed company, whose historical results are reflected as discontinued operations for periods before that date.

From Becton Dickinson's annual report on Form 10-K for the year ended 30 September 2025. The filing

Compare with another name What $10,000 in Becton Dickinson became

Latest results

Latest quarterQ3 FY2026ended 30 June 2026 · 10-Q filed 6 August 2026
Revenue
$5.0 billion
-9.5% on the year · +5.7% on the quarter
Q4 FY2024Q3 FY2026
Net income
$377 million
-34.3% on the year
Q4 FY2024Q3 FY2026
Diluted EPS
$1.37
-31.5% on the year
Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

Read the Q3 FY2026 results →the 10-Q on EDGAR ↗
Last full yearFY2025ended 30 September 2025 · 10-K filed 25 November 2025
Revenue
$21.8 billion
+8.2% on the year
FY2018FY2025
Net income
$1.7 billion
-1.6% on the year
FY2018FY2025
Diluted EPS
$5.82
-0.7% on the year
FY2018FY2025

this yearthe year beforeHover a bar for its figure.

The years before, in wordsBecton Dickinson (BDX) reported revenue of $21.8 billion for fiscal 2025, the year ended 30 September 2025, up 8.2% on the year before. Net income was $1.7 billion and diluted earnings per share $5.82. Revenue was $20.2 billion in fiscal 2024, $19.4 billion in fiscal 2023, $18.9 billion in fiscal 2022 and $19.1 billion in fiscal 2021. Net income in the same years was $1.7 billion, $1.5 billion, $1.8 billion and $2.1 billion. Over the twelve months to 30 June 2026, Becton Dickinson reported revenue of $20.8 billion and net income of $941 million. Revenue grew 6.3% a year, compounded, over the five years to fiscal 2025. Becton Dickinson declared $4.16 a share in dividends over the last four quarters and had 272 million shares outstanding at the latest filed count. At 30 June 2026 it carried $16.8 billion of debt and $708 million of cash. At the close of 6 November 2026 the market cap of Becton Dickinson was $57.7 billion, 63.8 times its earnings over the last twelve months.
Read the FY2025 results →the 10-K on EDGAR ↗

Ratios

From the filings

ROE3.9%
ROCE4.9%
Operating margin9.6%
Net margin4.5%
FCF marginn/a
Interest cover3.4x
Debt to equity0.69x
Cash conversionn/a
Share count, last 12 months-5.0%
Sales CAGR, 3 years5.0%
Profit CAGR, 3 years-1.9%
EPS, TTM$3.32

At the close of 6 November 2026

Price$211.81
Market cap$57.7 billion
Stock P/E63.8x
Price to book2.4x
EV / EBITDA16.6x
Dividend yield2.0%
Market cap / sales2.8x
52-week high$213.49
52-week low$140.71
Price, 1 year50.2%
Price CAGR, 3 years1.3%
Price CAGR, 5 years2.3%

29 ready-made ratios, from FCF yield to net debt to EBITDA, wait on the Formulas page, each with what it tells you. Browse and add them →

Worked from the filed figures; hover a name for the formula.
Read moreThe priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on the borrowing lines of Becton Dickinson & Co.'s balance sheet, added together, finance leases inside them only where the company puts them there; operating leases are a separate line. Nothing here is a valuation or a view.
BDXgreeksoup.ai
Daily prices to 6 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read moreData provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.

Quarterly results

Q4 FY2021 *Q1 FY2022 †Q2 FY2022 †Q3 FY2022Q4 FY2022 * †Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025 †Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue5,1364,7184,7504,6414,7614,5864,8214,8785,0874,7065,0454,9905,4375,1685,2725,5095,8915,2524,7144,983
Cost of revenue2,8482,4982,6372,5742,6842,4532,5862,7783,3852,6792,7412,6832,9502,9333,0152,8753,0922,8412,5602,668
Gross profit2,2882,2202,1132,0672,0772,1332,2352,1001,7022,0272,3042,3072,4872,2352,2572,6342,7992,4112,1542,315
Gross margin45%47%44%45%44%47%46%43%33%43%46%46%46%43%43%48%48%46%46%46%
R&D387314327315300313337306281290299299302343302297323306249258
SG&A1,3331,1851,1921,1491,1831,1871,2051,1901,1371,2131,1931,1961,2551,3181,2731,3201,3671,3931,2131,261
Operating income49669256453748958562854934943973460262245354688269855293.0663
Operating margin10%15%12%12%10%13%13%11%7%9%15%12%11%9%10%16%12%11%2%13%
Interest expense11298.097.099.0104102118119113111125137155155150152155153149132
Pre-tax income40260044242132048152947118135963350051330636370350939339.0554
Tax rate0%5%12%7%10%-6%13%14%15%21%15%3%22%1%15%18%3%3%195%18%
Net income265677454360288509460407108281537487400303308574493382-311377
Net margin5%14%10%8%6%11%10%8%2%6%11%10%7%6%6%10%8%7%-7%8%
Diluted EPS$0.84$2.28$1.50$1.18$0.92$1.70$1.53$1.36$0.37$0.96$1.85$1.68$1.45$1.04$1.07$2.00$1.72$1.34-$1.11$1.37
Operating cash flow951674444n/an/an/an/an/an/an/an/an/an/a693n/an/an/a657598651
Capital expenditure465183227243315208181191294116134179296105129174352108125143
Free cash flow486491217n/an/an/an/an/an/an/an/an/an/a588n/an/an/a549473508
Buybacksn/an/an/an/an/a0.00.00.00.05000.00.00.07500.00.02502502,0000.0
Dividends paid259271270271270281282286265275275275275302298299297299290286
Shares outstanding284m285m285m285m283m284m284m290m290m289m289m289m289m287m287m287m285m285m276m272m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Income statement (profit and loss)

FY2007FY2008 †FY2009 †FY2010 †FY2011 †FY2012 †FY2013FY2014 †FY2015 †FY2016FY2017 †FY2018 †FY2019FY2020 †FY2021 †FY2022FY2023FY2024FY2025TTM
Revenue6,2836,8986,9877,1247,5847,7088,0548,44610,28212,48312,09315,98317,29016,07419,13118,87019,37220,17821,84020,840
Cost of revenue3,0333,3573,3123,4283,6253,7553,8834,1455,5876,4926,1288,7219,0029,27610,50010,39311,20211,05311,91511,161
Gross profit3,2503,5403,6753,6963,9593,9534,1714,3014,6955,9915,9427,2628,2886,7988,6318,4778,1709,1259,9259,679
Gross margin51.7%51.3%52.6%51.9%52.2%51.3%51.8%50.9%45.7%48.0%49.1%45.4%47.9%42.3%45.1%44.9%42.2%45.2%45.4%46.4%
Research and developmentn/an/a4054234704724945506328287701,0061,0621,0391,2791,2561,2371,1901,2651,136
Selling, general and administrative1,5841,6701,6811,6911,8241,9232,4222,1452,5633,0052,9094,0154,3324,1854,7194,7094,7194,8575,2785,234
Operating income1,1851,4881,5901,5821,6661,5581,2541,6061,0741,4301,5221,5091,7609122,2502,2822,1112,3972,5792,006
Operating margin18.9%21.6%22.8%22.2%22.0%20.2%15.6%19.0%10.4%11.5%12.6%9.4%10.2%5.7%11.8%12.1%10.9%11.9%11.8%9.6%
Interest expense46.436.340.451.384.0135138135371388521706639528469398452528613589
Pre-tax income1,1851,4901,5791,5671,6181,4721,1651,5227391,0749761,1731,1764141,6921,7831,6622,0051,8811,495
Income tax34441241145241736323633744.097.0-124862-57.062.088.0148132300203205
Effective tax rate29.0%27.7%26.1%28.8%25.8%24.6%20.3%22.1%6.0%9.0%-12.7%73.5%-4.8%15.0%5.2%8.3%7.9%15.0%10.8%13.7%
Net income8901,1271,2321,3181,2711,1701,2931,1856959761,1003111,2338742,0921,7791,4841,7051,678941
Net margin14.2%16.3%17.6%18.5%16.8%15.2%16.1%14.0%6.8%7.8%9.1%1.9%7.1%5.4%10.9%9.4%7.7%8.4%7.7%4.5%
Diluted EPS$3.49$4.46$4.99$5.49$5.62$5.59$6.49$5.99$3.35$4.49$4.60$0.60$3.94$2.71$6.85$5.88$4.94$5.86$5.82$3.32
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
From each year's 10-K, linked; TTM is the last four quarters.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Revenue by segment FY2011 to FY2025

FY2011FY2012FY2013FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
Medical4,0074,0914,3064,5736,4607,9657,4198,6169,0647,6378,3618,8419,50210,07411,45652.5%
Interventionaln/an/an/an/an/a6896853,0373,9263,7624,2394,4644,7364,9805,21723.9%
Life Sciencesn/an/a3,7483,8723,8223,8293,9884,3304,3004,6756,5305,5645,1335,1915,16723.7%
Biosciences1,0961,080n/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Diagnostics2,4802,538n/an/an/an/an/an/an/an/an/an/an/an/an/an/a
MedicalInterventional FY2016 to FY2025Life Sciences FY2013 to FY2025Diagnostics FY2011 to FY2012Biosciences FY2011 to FY2012
7.6FY20118.1FY201310.3FY201512.1FY201717.3FY201919.1FY202119.4FY202321.8FY2025

$ billion; hover a block for its figure and share; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

Profit by segment FY2023 to FY2025

The operating profit each segment reports. Costs Becton Dickinson does not charge to a segment are left out, so the segments can add up to more than the company's own operating profit.

FY2023FY2024FY2025Margin
FY2025
Medical3,3523,5834,14036.1%
Interventional1,9392,1152,25343.2%
Life Sciences1,5991,6161,64131.8%
MedicalInterventionalLife Sciences
6,890FY20237,314FY20248,034FY2025

$ million; the figure over a bar is all the segments together. Hover a block for its profit, sales and margin.

FY2025Share of salesShare of profit
Medical52%52%
Interventional24%28%
Life Sciences24%20%

Each column adds to 100%. A segment with a bigger share of the profit than of the sales makes more on each dollar it sells.

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where every segment with sales that year has an operating profit figure. A margin is a segment's operating profit over its own sales.

Revenue by region FY2009 to FY2025

FY2009FY2010FY2011FY2012FY2013FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
United Statesn/a3,1693,2483,2883,3533,4175,0696,8936,5048,7689,7309,16110,37110,72211,11311,66312,79058.6%
EMEAn/an/an/an/an/an/an/an/an/an/a3,8373,7344,5484,0434,2444,4024,72921.7%
Greater Asian/an/an/an/a1,3441,4371,5451,6921,7442,4602,7262,3843,0693,0472,9132,9063,09314.2%
Othern/a9711,1131,1591,1681,2101,2341,2251,2571,4579977941,1421,0581,1021,2071,2275.6%
Asia Pacificn/a663793883n/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Europen/a2,3222,4312,3792,1892,3832,4342,6742,5883,298n/an/an/an/an/an/an/an/a
Segment Geographical Groups Of Countries Group Four885n/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Segment Geographical Groups Of Countries Group Three563n/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Segment, Geographical, Groups of Countries, Group One3,130n/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Segment, Geographical, Groups of Countries, Group Two2,408n/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a
United States FY2010 to FY2025EMEA FY2019 to FY2025Greater Asia FY2013 to FY2025Other FY2010 to FY2025Europe FY2010 to FY2018Asia Pacific FY2010 to FY2012Segment, Geographical, Groups of Countries, Group One FY2009Segment, Geographical, Groups of Countries, Group Two FY2009Segment Geographical Groups Of Countries Group Four FY2009Segment Geographical Groups Of Countries Group Three FY2009
7.1FY20108.1FY201312.5FY201617.3FY201918.9FY202221.8FY2025

$ billion; hover a block for its figure and share; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

First forecast against the result

Becton Dickinson's adjusted EPS landed at or above the top of the range in 4, inside it in 1 and under it in 2 of the 7 years shown (FY2015 to FY2025).

+4.8%FY2015−19.4%FY2020+3.8%FY2021−9.2%FY2022+0.9%FY2023+1.1%FY2024−1.4%FY2025
  • At or above the top of the range
  • Inside the range
  • Under the range

Each bar is the year's result against the top of its first forecast range, in per cent of the top. Hover a bar for the figures.

Fiscal yearFirst forecast
adjusted EPS		Result
FY2015$6.76 to $6.83$7.16
FY2020$12.50 to $12.65$10.20
FY2021$12.40 to $12.60$13.08
FY2022$12.30 to $12.50$11.35
FY2023$11.85 to $12.10$12.21
FY2024$12.70 to $13.00$13.14
FY2025$14.25 to $14.60$14.40
First forecast
The full-year range the company gave with its fourth-quarter results for the year before, before any later change to it.
Result
The figure the company reported for that year with its next fourth-quarter results.
Adjusted EPS
The company's own measure, which leaves out items it names, so it differs from the EPS in the tables above.
Years left out
Where the forecast or the result could not be read with confidence. Each figure in the table links to the results release it comes from.

Cash flow

FY2007FY2008 †FY2009 †FY2010 †FY2011 †FY2012 †FY2013FY2014 †FY2015 †FY2016FY2017 †FY2018 †FY2019FY2020 †FY2021 †FY2022FY2023FY2024FY2025TTM
Operating cash flow1,2401,6871,7171,7441,7161,760n/a1,7461,7302,5592,5502,8653,3303,5394,6472,6342,9893,7983,430n/a
Capital expenditure5565965855315094875225925966937278959577691,194973874725760728
Free cash flow6841,0911,1321,2131,2071,273n/a1,1541,1341,8661,8231,9702,3732,7703,4531,6612,1153,0732,670n/a
Free cash flow margin10.9%15.8%16.2%17.0%15.9%16.5%n/a13.7%11.0%14.9%15.1%12.3%13.7%17.2%18.0%8.8%10.9%15.2%12.2%n/a
Cash from investingn/an/an/an/an/an/an/a-948-8,318-669-883-15,733-741-1,232-1,880n/a-716-5,514-818n/a
Cash from financingn/an/an/an/an/an/an/a-8076,190-1,76110,977-58.0-3,22322.0-3,306n/a-1,9562,087-3,617n/a
Depreciation and amortisation4414724654914945115465628911,1141,0881,9782,2532,1152,2302,2292,2882,2862,4622,454
Share-based compensation10810186.679.473.089.0100113166196174322261236229233259247258259
Buybacks4504505507501,5001,5004504000.00.02200.00.00.01,7505000.05001,0002,500
Dividends paid2402793173463613683864214855626779279841,0261,0481,0821,1141,1001,1961,172
Dividend per sharen/a$1.14$1.32$1.48n/an/a$1.98$2.18$2.40$2.64$2.92$3.00$3.08$3.16$3.32$3.48$3.64$3.80$4.16n/a
Diluted shares, weightedn/a253m247m240m226m209m199m198m208m218m224m265m275m282m292m287m288m291m289m275m
Shares outstanding at period endn/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a272m
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
Cash paid in the year, from the cash flow statement.
Read moreThe dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet

FY2007FY2008 †FY2009 †FY2010 †FY2011 †FY2012 †FY2013FY2014 †FY2015 †FY2016FY2017 †FY2018 †FY2019FY2020 †FY2021 †FY2022FY2023FY2024FY2025TTM
Funded by
Shareholders' equityn/a4,9365,1435,4354,8284,1365,0435,0537,1647,63312,94820,99421,08123,76523,67725,28225,79625,89025,39024,416
Debtn/an/a1,6891,6982,7204,1663,9703,97112,82211,55118,87021,49519,39017,93117,61016,06515,87920,11019,18116,808
Operating lease liabilitiesn/an/an/an/an/an/an/an/an/an/an/an/an/a336344384414667704n/a
Other liabilitiesn/a2,9772,4732,5182,8833,0593,1363,3606,4926,4025,91611,41511,29411,98012,23511,20310,69110,61910,0509,507
Total liabilities and equityn/a7,9139,3059,65110,43011,36112,14912,38426,47825,58637,73453,90451,76554,01253,86652,93452,78057,28655,32550,731
Owned
Fixed assetsn/a2,7442,9673,1003,2113,3043,4763,6054,0603,9014,6385,3755,6595,9236,0036,0126,5576,8216,9976,083
Goodwilln/a6266227649911,0761,1091,0907,5377,4197,56323,60023,37623,62023,90124,62124,52226,46526,61225,944
Intangible assetsn/an/an/an/an/an/an/an/an/an/an/an/an/a13,76712,73712,26410,90110,8719,3898,020
Cash and equivalents5118301,3941,2161,1751,6711,8901,8611,4241,54114,1791,1405362,8252,2831,0061,4161,717641708
Receivablesn/an/an/a1,2051,2291,2501,2401,1871,6181,6181,7442,3192,3452,3982,3502,1912,5343,0332,9942,364
Inventoryn/a1,0801,1571,1451,2451,2411,4021,4951,9591,7191,8182,4512,5792,7432,7433,2243,2733,8433,8943,316
Other assetsn/a2,6323,1652,2202,5792,8203,0323,1469,8809,3887,79219,01917,2702,7363,8493,6163,5774,5364,7984,296
Total assetsn/a7,9139,3059,65110,43011,36112,14912,38426,47825,58637,73453,90451,76554,01253,86652,93452,78057,28655,32550,731
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
At the fiscal year end; the TTM column is the latest quarter end.
Read moreBoth totals are the company's own. Other liabilities is the filed total less the rows above it: payables, deferred revenue, taxes, borrowings the rows above do not carry and the rest; other assets is the same on the other side. Investments add the current and non-current lines as filed. Debt is the company's own stated total where it files one, otherwise its long-term debt with the current maturities, never parts added together. A row is left blank in a year where the lines shown overlap and the remainder would fall below nil.

Compounded growth

10 years5 years3 yearsTTM
Sales growth, compounded7.8%6.3%5.0%-2.6%
Profit growth, compounded9.2%13.9%-1.9%-40.6%
Return on equity, average6.7%7.0%6.3%6.6%
Yearly growth, compounded; TTM is the last four quarters against the four before.
Read moreReturn on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Questions

What was Becton Dickinson's revenue in fiscal 2025?

Becton Dickinson (BDX) reported revenue of $21.8 billion for fiscal 2025, the year ended 30 September 2025, up 8.2% on the year before.

How much did Becton Dickinson earn in fiscal 2025?

Net income was $1.7 billion for fiscal 2025, and diluted earnings per share $5.82.

What is Becton Dickinson's P/E ratio?

At the close of 6 November 2026, Becton Dickinson traded at 63.8 times its earnings over the twelve months to 30 June 2026.

What is Becton Dickinson's market cap?

The market cap of Becton Dickinson was $57.7 billion at the close of 6 November 2026.

Does Becton Dickinson pay a dividend?

Yes. Becton Dickinson declared $4.16 a share in dividends over the four quarters to 30 June 2026.

Peers: Medical Equipment

CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Stryker Corp. SYK$124.0 billion34.7015.4%20.7%7.9%0.641.1%
3M Co. MMM$95.7 billion27.6185.7%18.8%1.7%3.631.7%
Boston Scientific Corp. BSX$62.0 billion18.1113.7%18.7%8.9%0.47n/a
Becton Dickinson & Co. BDX$57.7 billion63.803.9%9.6%-2.6%0.692.0%
Medline Inc. MDLN$52.2 billion57.614.9%5.7%n/a1.07n/a
Resmed Inc. RMD$33.1 billion21.4226.8%33.0%9.0%0.071.0%
Dexcom Inc. DXCM$29.6 billion31.1439.1%24.0%13.0%0.49n/a
West Pharmaceutical Services Inc. WST$27.9 billion44.8721.5%23.0%12.6%0.070.2%
Solventum Corp. SOLV$15.4 billion101.513.2%5.6%-2.8%1.05n/a
Baxter International Inc. BAX$13.3 billionn/a-11.1%-1.9%5.3%1.322.0%
Glaukos Corp. GKOS$13.3 billionn/a-23.7%-25.5%46.9%0.00n/a
Penumbra Inc. PEN$12.6 billion80.459.9%12.1%17.0%0.00n/a
All 110 in Medical Equipment
CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Intuitive Surgical Inc. ISRG$156.9 billion54.7518.5%28.4%20.5%0.00n/a
Medtronic plc MDT$130.3 billion25.0710.4%18.1%9.8%0.562.8%
Stryker Corp. SYK$124.0 billion34.7015.4%20.7%7.9%0.641.1%
3M Co. MMM$95.7 billion27.6185.7%18.8%1.7%3.631.7%
Boston Scientific Corp. BSX$62.0 billion18.1113.7%18.7%8.9%0.47n/a
Edwards Lifesciences Corp. EW$58.8 billion57.679.4%21.6%13.4%0.06n/a
Becton Dickinson & Co. BDX$57.7 billion63.803.9%9.6%-2.6%0.692.0%
Medline Inc. MDLN$52.2 billion57.614.9%5.7%n/a1.07n/a
GE HealthCare Technologies Inc. GEHC$37.2 billion17.3818.5%13.3%6.9%0.860.2%
Resmed Inc. RMD$33.1 billion21.4226.8%33.0%9.0%0.071.0%
Dexcom Inc. DXCM$29.6 billion31.1439.1%24.0%13.0%0.49n/a
Koninklijke Philips N.V. PHG *$29.2 billion29.228.2%8.0%-1.0%0.741.3%
West Pharmaceutical Services Inc. WST$27.9 billion44.8721.5%23.0%12.6%0.070.2%
Steris plc STE$24.5 billion29.9311.4%19.0%8.1%0.261.0%
Zimmer Biomet Holdings, Inc. ZBH$20.0 billion26.736.0%13.6%7.0%0.590.9%
Solventum Corp. SOLV$15.4 billion101.513.2%5.6%-2.8%1.05n/a
Smith & Nephew plc SNN *$13.7 billion21.7611.8%12.9%6.1%0.592.4%
Baxter International Inc. BAX$13.3 billionn/a-11.1%-1.9%5.3%1.322.0%
Glaukos Corp. GKOS$13.3 billionn/a-23.7%-25.5%46.9%0.00n/a
Penumbra Inc. PEN$12.6 billion80.459.9%12.1%17.0%0.00n/a
Cooper Companies, Inc. COO$11.9 billion21.296.8%12.8%4.7%0.31n/a
Align Technology Inc. ALGN$11.7 billion24.1711.4%14.9%4.4%0.00n/a
Insulet Corp. PODD$10.2 billion23.8727.2%18.4%26.5%0.61n/a
Globus Medical Inc. GMED$9.5 billion17.4511.6%21.6%13.4%0.00n/a
Bausch & Lomb Corp. BLCO$7.1 billionn/a-1.7%7.1%8.9%0.79n/a
MSA Safety Inc. MSA$6.6 billion21.8621.1%20.2%8.1%0.781.3%
Teleflex Inc. TFX$6.0 billion18.338.7%9.4%20.9%0.460.9%
Haemonetics Corp. HAE$5.5 billion53.8311.6%12.8%4.1%1.26n/a
Merit Medical Systems Inc. MMSI$5.2 billion32.809.2%13.5%9.1%0.42n/a
LivaNova plc LIVN$5.0 billion30.0114.3%10.7%11.7%0.22n/a
MiniMed Group, Inc. MMED$4.7 billionn/an/an/an/a0.00n/a
Heartflow, Inc. HTFL$4.5 billionn/a-42.3%-37.8%n/a0.00n/a
Integer Holdings Corp. ITGR$4.3 billion42.486.0%8.2%-0.3%0.71n/a
ICU Medical Inc. ICUI$4.3 billion71.992.8%5.1%-5.9%0.53n/a
Envista Holdings Corp. NVST$4.0 billion6.5120.5%25.4%9.8%0.46n/a
Pulse Biosciences, Inc. PLSE$3.9 billionn/a-45.6%-5,821.1%1,637.2%0.00n/a
Warby Parker Inc. WRBY$3.2 billion424.581.9%0.2%9.9%0.00n/a
TransMedics Group, Inc. TMDX$3.1 billion23.8926.2%11.9%28.5%0.930.0%
iRhythm Holdings, Inc. IRTC$3.0 billionn/a-21.8%-5.7%21.6%3.68n/a
Axogen, Inc. AXGN$3.0 billionn/a-6.4%-5.2%24.3%0.00n/a
AtriCure, Inc. ATRC$3.0 billion195.032.8%2.9%13.8%0.11n/a
UFP Technologies Inc. UFPT$2.3 billion30.9015.8%15.5%8.6%0.20n/a
Establishment Labs Holdings Inc. ESTA$2.0 billionn/a-246.6%-6.6%38.3%17.17n/a
Dentsply Sirona Inc. XRAY$1.9 billionn/a-8.9%-1.5%-1.4%1.626.8%
Lemaitre Vascular Inc. LMAT$1.9 billion29.4214.7%27.7%11.8%0.391.2%
Inspire Medical Systems, Inc. INSP$1.8 billion18.5712.2%1.8%-0.2%0.00n/a
Kestra Medical Technologies, Ltd. KMTS$1.7 billionn/a-67.4%-134.5%60.7%0.33n/a
Butterfly Network, Inc. BFLY$1.7 billionn/a-29.1%-46.9%39.3%0.000.0%
Enovis Corp. ENOV$1.6 billionn/a-35.3%-20.6%3.3%0.84n/a
NovoCure Ltd. NVCR$1.6 billionn/a-34.7%-17.2%12.9%0.56n/a
Conmed Corp. CNMD$1.5 billion21.306.9%9.9%1.6%0.771.2%
National Vision Holdings, Inc. EYE$1.4 billion29.335.6%4.1%7.8%0.26n/a
Cadre Holdings, Inc. CDRE$1.4 billion34.4211.2%10.7%18.3%1.011.2%
Staar Surgical Co. STAA$1.3 billion1,815,851,369,755,783,936.000.1%0.2%42.4%0.00n/a
Procept BioRobotics Corp. PRCT$1.2 billionn/a-34.9%-33.6%17.5%0.16n/a
Tandem Diabetes Care Inc. TNDM$1.2 billionn/a-36.4%-2.4%6.8%4.47n/a
Alphatec Holdings, Inc. ATEC$1.2 billionn/an/a-3.6%15.3%n/an/a
Iradimed Corp. IRMD$1.1 billion46.1422.5%32.3%11.0%0.000.9%
Si-Bone, Inc. SIBN$1.1 billionn/a-7.4%-7.6%14.0%0.190.0%
Integra LifeSciences Holdings Corp. IART$1.0 billion78.971.2%4.4%0.8%1.71n/a
Ceribell, Inc. CBLL$1.0 billionn/a-62.9%-69.8%31.3%0.17n/a
Artivion, Inc. AORT$986 millionn/a-3.9%2.3%14.0%0.81n/a
Bioventus Inc. BVS$893 million13.2523.8%9.7%3.9%0.96n/a
Beta Bionics, Inc. BBNX$855 millionn/a-20.7%-72.7%43.7%0.00n/a
Orthopediatrics Corp. KIDS$828 millionn/a-10.0%-9.4%16.1%0.31n/a
Tactile Systems Technology Inc. TCMD$585 million25.2610.5%9.4%14.4%0.00n/a
Sight Sciences, Inc. SGHT$558 millionn/a-57.8%-29.5%16.2%0.83n/a
Anteris Technologies Global Corp. AVR$553 millionn/a-41.2%-4,738.4%-9.6%0.00n/a
Delcath Systems, Inc. DCTH$517 million1,494.000.4%-1.9%35.8%0.00n/a
Avita Medical, Inc. RCEL$513 millionn/an/a-33.9%17.0%n/an/a
Angiodynamics Inc. ANGO$497 millionn/a-20.1%-11.2%8.2%0.00n/a
Mimedx Group, Inc. MDXG$482 millionn/a-9.1%-8.3%-22.8%0.00n/a
SS Innovations International, Inc. SSII$430 millionn/a-23.3%-15.8%89.7%0.00n/a
NeuroPace Inc. NPCE$428 millionn/a-160.9%-15.3%11.6%4.970.0%
Shoulder Innovations, Inc. SI$426 millionn/a-28.2%-54.4%n/a0.13n/a
Cerus Corp. CERS$407 millionn/a-9.7%-1.0%n/a0.84n/a
Carlsmed, Inc. CARL$395 millionn/a-43.1%-61.1%n/a0.18n/a
Mobia Medical, Inc. MOBI$372 millionn/an/an/an/a0.05n/a
Embecta Corp. EMBC$350 million4.18n/a21.9%-7.6%n/a7.4%
Orchestra BioMed Holdings, Inc. OBIO$341 millionn/a-305.5%-181.4%986.1%1.80n/a
Orthofix Medical Inc. OFIX$320 millionn/a-14.4%-4.7%3.0%0.52n/a
CapsoVision, Inc. CV$316 millionn/a-226.6%-217.1%n/a0.00n/a
Cytosorbents Corp. CTSO$308 millionn/an/a-34.7%3.1%n/an/a
Sanara MedTech Inc. SMTI$291 millionn/a-403.0%n/a12.9%5.85n/a
ClearPoint Neuro, Inc. CLPT$276 millionn/a-132.5%-70.6%32.5%1.86n/a
InfuSystem Holdings, Inc. INFU$272 million33.3414.4%9.3%2.5%0.35n/a
Treace Medical Concepts, Inc. TMCI$265 millionn/a-90.5%-24.4%-7.1%0.91n/a
Profound Medical Corp. PROF$264 millionn/a-76.4%-145.1%65.3%0.11n/a
Orasure Technologies Inc. OSUR$238 millionn/a-15.5%-48.1%-18.9%0.00n/a
Utah Medical Products Inc. UTMD$231 million22.138.6%28.4%-7.0%0.00n/a
Electromed, Inc. ELMD$226 million20.5820.9%18.8%15.3%0.00n/a
PRO DEX Inc. PDEX$202 million17.3524.4%16.8%13.3%0.33n/a
TriSalus Life Sciences, Inc. TLSI$200 millionn/a-430.7%-67.7%25.2%5.05n/a
Anika Therapeutics, Inc. ANIK$195 millionn/a-1.3%-2.1%9.4%0.00n/a
RxSight, Inc. RXST$190 millionn/a-20.9%-50.4%-14.3%0.00n/a
Inogen Inc. INGN$161 millionn/a-14.1%-8.7%3.2%0.00n/a
Edap TMS SA FOCL$158 millionn/a-104.3%-35.4%n/a0.99n/a
Koru Medical Systems, Inc. KRMD$143 millionn/a-10.1%-3.7%22.4%0.00n/a
Apyx Medical Corp. APYX$124 millionn/a-87.6%-5.5%24.4%3.89n/a
Pulmonx Corp. LUNG$112 millionn/a-124.4%-44.4%-3.2%1.11n/a
Stereotaxis, Inc. STXS$111 millionn/a-182.3%-75.7%-5.5%0.00n/a
SkinHealth Systems Inc. SKIN$102 millionn/a-32.8%2.4%-4.4%4.36n/a
Lakeland Industries Inc. LAKE$88 millionn/a-21.4%-4.1%-0.4%0.23n/a
Outset Medical, Inc. OM$79 millionn/a-85.4%-51.2%1.6%1.18n/a
Neuraxis, Inc. NRXS$77 millionn/a-114.0%-144.5%65.2%0.01n/a
Lucid Diagnostics Inc. LUCD$76 millionn/a-478.3%-930.8%24.9%2.15n/a
Lensar, Inc. LNSR$66 millionn/a232.8%-13.5%3.3%0.25n/a
NutriBand Inc. NTRB$66 millionn/a-130.7%-435.6%-37.3%0.00n/a
RenovoRx, Inc. RNXT$55 millionn/a-140.2%-489.0%n/a0.00n/a
PAVmed Inc. PAVM$10 millionn/a-34.5%-23,841.1%-89.0%0.43n/a
70 companies share its SEC industry code (Surgical & Medical Instruments & Apparatus); the rest are the names nearest in size in its wider industry, Medical Equipment, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read moreBy market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.

The public record on BDX

Dividends$1.20 billion paid in cash dividends in FY2025
Filings34 in twelve months: 21 current reports (8-K), about 7 officer or director change; 6 regulation FD disclosure; 5 results of operations; 4 other events; 2 material agreement
Planned insider sales26 Form 144 notices in twelve months, $8.7 million; latest 5 November 2026
Options tapeput/call 0.6 by open interest at the 6 November 2026 close; the straddle prices a 4.8% move to 20 November 2026
13F holders1,450 funds reported a position for the quarter to 30 June 2026; largest First Eagle Investment Management, LLC
Insider trading21 sales and 0 purchases on Form 4 in twelve months
Congress1 House trade disclosed in six months
Short interest8.9 million shares short, 5.48 days to cover at 15 October 2026
Documentsthe 10-K, the 10-Qs, the proxy and 5 earnings press releases, each linked

Filings

FilingPeriodFiledWhere
10-Q30 June 20266 August 2026EDGAR
10-Q31 March 20267 May 2026EDGAR
10-Q31 December 20259 February 2026EDGAR
10-K30 September 202525 November 2025EDGAR
10-Q30 June 20257 August 2025EDGAR
10-Q31 March 20251 May 2025EDGAR
10-Q31 December 20246 February 2025EDGAR
10-K30 September 202427 November 2024EDGAR
10-Q30 June 20241 August 2024EDGAR
10-Q31 March 20242 May 2024EDGAR

Reading about a stock somewhere else? Our free Chrome extension, GreekSoup Stock Ticker Lookup: Earnings, Insider Trades, 13F Holders, shows the latest quarter against a year ago, insider trades and 13F holders when you hover a $ticker such as $AAPL.